TRIB
TRINITY BIOTECH PLCPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- E Jul 23 Trading halt: Trading Halt: TRIB — T1 (News Pending)
- X Jul 31 Short interest falls 95.3% to 17.1K
- R Aug 14 Trinity Biotech secured a $7.0M investment from Perceptive Advisors…
- X Aug 14 Short interest falls 45.9% to 9.3K
- R Aug 21 Trinity Biotech filed Post-Effective Amendment No. 2 to its F-1 regi…
- R Aug 28 Trinity Biotech filed a 6-K providing a business update and disclosi…
- R Sep 2 Trinity Biotech's F-1 registration statement (File No. 333-293717) b…
- X Sep 30 Short interest jumps 123.3% to 17.9K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 1 trimmed or exited.
- Short sellersBUILDING
Short interest +123.3% to 17.9K shares. 2.1 days to cover, ≈2.2% of shares.
- TrendRANGE
9% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| RHUMBLINE ADVISERS | ADD | $3.6K |
| SIMPLEX TRADING, LLC | TRIM | $137.00 |
| UBS Group AG | ADD | $546.00 |
| MORGAN STANLEY | TRIM | $218.00 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | $16.0K |
| RHUMBLINE ADVISERS | DOUBLED | $5.0K |
| OSAIC HOLDINGS, INC. | TRIM | $2.0K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | $867.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Sep 30, 2026| Oct 1, 2026 | Volatility Pause | Resumed |
| Jul 23, 2026 | Resumption Scheduled | Resumed |
SecBot reports
21 filings · 1 press release · 3 bullish · 7 bearish · 3 mixed · 8 neutral- NEUTRAL 6-KOct 5, 2026
Trinity Biotech filed a 6-K reporting the results of its annual general meeting held on September…
No material business or financial changes reported. Monitor future filings for operational updates or financial results.
- NEUTRAL 6-KSep 9, 2026
Trinity Biotech's Trinovium subsidiary signed a contract with Red Team Investments to supply…
This is an early-stage pilot with no disclosed revenue or financial terms — the stock may see speculative interest given the AI data center narrative, but there is no near-term revenue catalyst…
- BULLISH EFFECTSep 2, 2026
Trinity Biotech's F-1 registration statement (File No. 333-293717) became effective on September…
The effectiveness of the F-1 shelf, combined with the termination of the dilutive ATM facility, removes a major overhang on TRIB. Monitor for any new offering announcements under the shelf and for…
- BEARISH 6-KAug 28, 2026
Trinity Biotech filed a 6-K providing a business update and disclosing receipt of a Nasdaq…
The delisting notice is the primary catalyst — monitor for the hearing date and any updates on the 'advanced stage' strategic transactions the company claims will restore MVPHS compliance. The…
All TRIB filing & press-release reports (22)
- 6-K reportOct 5, 2026
- 6-K reportSep 9, 2026
- EFFECT reportSep 2, 2026
- 6-K reportAug 28, 2026
- F-1/A reportAug 21, 2026
- 6-K reportAug 17, 2026
- 6-K reportAug 14, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 2, 2026
- 6-K reportJun 30, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 18, 2026
- PRESS-RELEASE reportJun 16, 2026
- 6-K reportJun 12, 2026
- 424B5 reportJun 12, 2026
- EFFECT reportJun 11, 2026
- F-1/A reportJun 3, 2026
- EFFECT reportMay 26, 2026
- PRESS-RELEASE reportMar 23, 2026
- EFFECT reportMar 4, 2026
- F-1 reportFeb 25, 2026